phase readout
saveNCT03962543: MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
ACTIVE_NOT_RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Phase: PHASE2. Conditions: Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
view source ↗
comments(0)
5-min edit window · permanent after that